These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 2582017)

  • 21. Oral tocainide versus disopyramide: a double-blind, randomized, crossover study of outpatients with stable ventricular premature beats.
    McLaran CJ; Hossack KF; Neilson GH; Siskind V
    J Cardiovasc Pharmacol; 1984; 6(4):657-62. PubMed ID: 6206321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effect of disopyramide and ethmozine in suppressing complex ventricular arrhythmias by use of a double-blind, placebo-controlled, longitudinal crossover design.
    Pratt CM; Young JB; Francis MJ; Taylor AA; Norton HJ; English L; Mann DE; Kopelen H; Quinones MA; Roberts R
    Circulation; 1984 Feb; 69(2):288-97. PubMed ID: 6360413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Propafenone versus disopyramide: a double-blind randomized crossover trial in patients presenting chronic ventricular arrhythmias.
    Libersa C; Caron J; Pladys A; Beuscart R; Kacet S; Wajman A; Connell C; Dupuis B; Lekieffre J
    Clin Cardiol; 1987 Jul; 10(7):405-10. PubMed ID: 2440632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of ectopic atrial arrhythmias and premature atrial complexes in adults with encainide.
    Pool PE; Quart BD
    Am J Cardiol; 1988 Dec; 62(19):60L-62L. PubMed ID: 2462340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of disopyramide and mexiletine used alone and in combination for ventricular arrhythmias in patients with and without overt heart disease.
    Tanabe T; Takahashi K; Yoshioka K; Goto Y
    Int J Cardiol; 1991 Sep; 32(3):303-12. PubMed ID: 1724233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electrophysiologic and clinical effects of intravenous and oral encainide in accessory atrioventricular pathway.
    Kunze KP; Kuck KH; Schlüter M; Kuch B; Bleifeld W
    Am J Cardiol; 1984 Aug; 54(3):323-9. PubMed ID: 6431796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
    Bigger JT
    Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosing recommendations for encainide.
    Antonaccio MJ; Verjee S
    Am J Cardiol; 1986 Aug; 58(5):114C-116C. PubMed ID: 3092615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy of oral encainide in frequent and repetitive ventricular arrhythmias.
    Bongiorni MG; Levorato D; Arlotta C; Paperini L; Contini C
    Eur Heart J; 1988 Jul; 9(7):765-76. PubMed ID: 3139413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
    Cardiac Arrhythmia Suppression Trial (CAST) Investigators
    N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dihydroquinidine versus disopyramide: efficacy in patients with chronic stable ventricular ectopy.
    Chimienti M; Panciroli C; Salerno JA; Regazzi-Bonora M; Previtali M; Cristiani D; Rondanelli R; Bobba P
    Clin Cardiol; 1984 Oct; 7(10):538-46. PubMed ID: 6386253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical studies of Norpace (Part XI).
    Nisbet T
    Angiology; 1975 Jan; 26(1 Pt 2):149-53. PubMed ID: 46729
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy of and adverse effects of disopyramide. Comparison of capsules, controlled release tablets and placebo in patients with chronic ventricular arrhythmias.
    Ekelund LG; Nilsson E; Walldius G
    Eur J Clin Pharmacol; 1986; 29(6):673-7. PubMed ID: 3519236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemodynamic effects of encainide in patients with ventricular arrhythmia and poor ventricular function.
    Sami MH; Derbekyan VA; Lisbona R
    Am J Cardiol; 1983 Sep; 52(5):507-11. PubMed ID: 6412535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Encainide for cardiac arrhythmias.
    Med Lett Drugs Ther; 1987 May; 29(740):50-2. PubMed ID: 2437434
    [No Abstract]   [Full Text] [Related]  

  • 36. Electrophysiology of oral encainide.
    Jackman WM; Zipes DP; Naccarelli GV; Rinkenberger RL; Heger JJ; Prystowsky EN
    Am J Cardiol; 1982 Apr; 49(5):1270-8. PubMed ID: 6801954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of propafenone and disopyramide in the treatment of ventricular premature complexes: a randomized double blind crossover placebo controlled trial.
    Rabkin SW; Boroomand-Rashti K; McKinnon J; Rotem CE
    Can J Cardiol; 1987 Apr; 3(3):105-10. PubMed ID: 3297265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relation of blood level and metabolites to the antiarrhythmic effectiveness of encainide.
    Harrison DC; Kates RE; Quart BD
    Am J Cardiol; 1986 Aug; 58(5):66C-73C. PubMed ID: 3092622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience of encainide (MJ 9067): a new anti-arrhythmic drug.
    Kesteloot H; Stroobandt R
    Eur J Clin Pharmacol; 1979 Nov; 16(5):323-6. PubMed ID: 93050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of encainide and metabolizer phenotype on ventricular conduction during exercise.
    Karalis DG; Nydegger C; Porter RS; Carver J; Pina IL; Kutalek SP; Michelson EL
    Am J Cardiol; 1990 Dec; 66(19):1393-6. PubMed ID: 2123075
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.